Gene Therapy

Turner, Alice

doi:10.1016/b978-0-12-803942-7.00014-3

Alpha-1-Antitrypsin Deficiency 2017

DOI: 10.1016/b978-0-12-803942-7.00014-3

|View full text |Cite

Gene Therapy

Alice Turner¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

2020

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency

Pye

Turner

2019

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

IntroductionAlpha-1 antitrypsin deficiency (AATD) is most often associated with chronic lung disease, early onset emphysema and liver disease. The standard of care in lung disease due to AATD is alpha-1 antitrypsin augmentation but there are several new and emerging treatment options under investigation for both lung and liver manifestations. Areas coveredWe review therapeutic approaches to lung and liver disease in alpha-1 antitrypsin deficiency (AATD) and the agents in clinical development according to their mode of action.The focus is on products in clinical trials, but data from pre-clinical studies is described where relevant, particularly where progression to trials appears likely. Expert opinionClinical trials directed at lung and liver disease separately are now taking place. Multimodality treatment may be the future, but this could be limited by treatment costs. The next 5-10 years may reveal new guidance on when to use therapeutics for slowing disease progression with personalized treatment regimes coming to the forefront.

show abstract

Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency

Pye

Turner

2019

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

show abstract

Personalizing liver targeted treatments and transplantation for patients with alpha-1 antitrypsin deficiency

Pye

Khan

Whitehouse

et al. 2020

Expert Review of Precision Medicine and Drug Development

View full text Add to dashboard Cite

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.When citing, please reference the published version. Take down policyWhile the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Gene Therapy

Cited by 2 publications

References 66 publications

Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency

Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency

Personalizing liver targeted treatments and transplantation for patients with alpha-1 antitrypsin deficiency

Contact Info

Product

Resources

About